US HB6275 | 2023-2024 | 118th Congress
Status
Spectrum: Partisan Bill (Democrat 3-0)
Status: Introduced on November 7 2023 - 25% progression
Action: 2023-11-10 - Referred to the Subcommittee on Innovation, Data, and Commerce.
Pending: House Subcommittee on Innovation, Data, and Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on November 7 2023 - 25% progression
Action: 2023-11-10 - Referred to the Subcommittee on Innovation, Data, and Commerce.
Pending: House Subcommittee on Innovation, Data, and Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
Title
Protecting Consumer Access to Generic Drugs Act of 2023
Sponsors
| Rep. Marie Gluesenkamp Perez [D-WA] | Rep. Sean Casten [D-IL] | Rep. Gerald Connolly [D-VA] |
History
| Date | Chamber | Action |
|---|---|---|
| 2023-11-10 | House | Referred to the Subcommittee on Innovation, Data, and Commerce. |
| 2023-11-07 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2023-11-07 | House | Introduced in House |
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/118th-congress/house-bill/6275/all-info |
| Text | https://www.congress.gov/118/bills/hr6275/BILLS-118hr6275ih.pdf |
